Swiss Life Asset Management Ltd Sells 18,316 Shares of Labcorp Holdings Inc. $LH

Swiss Life Asset Management Ltd lessened its stake in Labcorp Holdings Inc. (NYSE:LH) by 49.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,713 shares of the medical research company’s stock after selling 18,316 shares during the period. Swiss Life Asset Management Ltd’s holdings in Labcorp were worth $4,695,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Kepler Cheuvreux Suisse SA bought a new stake in shares of Labcorp in the 4th quarter valued at about $3,389,000. Dynamic Wealth Strategies LLC grew its position in shares of Labcorp by 28.3% in the 4th quarter. Dynamic Wealth Strategies LLC now owns 862 shares of the medical research company’s stock valued at $216,000 after buying an additional 190 shares during the last quarter. NewEdge Wealth LLC bought a new stake in shares of Labcorp in the 4th quarter valued at about $242,000. Crossmark Global Holdings Inc. grew its position in shares of Labcorp by 32.8% in the 4th quarter. Crossmark Global Holdings Inc. now owns 3,992 shares of the medical research company’s stock valued at $1,002,000 after buying an additional 985 shares during the last quarter. Finally, Ethic Inc. grew its position in shares of Labcorp by 13.2% in the 4th quarter. Ethic Inc. now owns 12,626 shares of the medical research company’s stock valued at $3,168,000 after buying an additional 1,468 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Robert W. Baird set a $334.00 target price on Labcorp in a research note on Friday, May 1st. JPMorgan Chase & Co. increased their price target on Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Evercore reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Piper Sandler boosted their target price on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $308.00.

Labcorp Stock Down 1.1%

Labcorp stock opened at $254.40 on Thursday. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a 12-month low of $239.67 and a 12-month high of $293.72. The firm’s fifty day moving average is $266.53 and its 200 day moving average is $265.91. The company has a market capitalization of $20.86 billion, a PE ratio of 22.53, a PEG ratio of 1.80 and a beta of 0.91.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. Labcorp’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, sell-side analysts predict that Labcorp Holdings Inc. will post 17.99 EPS for the current fiscal year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be issued a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a yield of 1.1%. Labcorp’s dividend payout ratio is presently 25.51%.

Insiders Place Their Bets

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president owned 2,579 shares in the company, valued at approximately $734,782.89. This represents a 17.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brian J. Caveney sold 1,500 shares of the stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the completion of the transaction, the executive vice president owned 30,107 shares in the company, valued at approximately $8,619,935.17. The trade was a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 16,656 shares of company stock worth $4,524,961. Corporate insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.